share_log

Checkpoint Therapeutics FY23 EPS $(3.17) Vs $(7.09) YoY; As Of December 31, 2023, Checkpoint's Cash And Cash Equivalents Totaled $4.9M

Checkpoint Therapeutics FY23 EPS $(3.17) Vs $(7.09) YoY; As Of December 31, 2023, Checkpoint's Cash And Cash Equivalents Totaled $4.9M

Checkpoint Therapeutics23财年每股收益为3.17美元,同比增长7.09美元;截至2023年12月31日,Checkpoint的现金和现金等价物总额为490万美元
Benzinga ·  03/22 08:38

Financial Results:

财务业绩:

  • Cash Position: As of December 31, 2023, Checkpoint's cash and cash equivalents totaled $4.9 million, compared to $12.1 million at December 31, 2022, a decrease of $7.2 million. This cash position is not reflective of the registered direct offering that closed in January 2024 for total gross proceeds of approximately $14.0 million.
  • R&D Expenses: Research and development expenses for the year ended December 31, 2023, were $43.6 million, compared to $49.8 million for the year ended December 31, 2022, a decrease of $6.2 million. Research and development expenses for the year ended December 31, 2023 included $4.6 million of non-cash stock expenses, compared to $2.8 million in non-cash stock expenses for the year ended December 31, 2022.
  • G&A Expenses: General and administrative expenses for both the years ended December 31, 2023 and December 31, 2022, were $8.7 million. General and administrative expenses for the year ended December 31, 2023 included $2.7 million of non-cash stock expenses, compared to $2.5 million in non-cash stock expenses for the year ended December 31, 2022.
    • Net Loss: Net loss attributable to common stockholders for the year ended December 31, 2023, was $51.8 million, or $3.17 per share, compared to a net loss of $62.6 million, or $7.09 per share, for the year ended December 31, 2022.
  • 现金状况:截至2023年12月31日,Checkpoint的现金及现金等价物总额为490万美元,而截至2022年12月31日为1,210万美元,减少了720万美元。该现金状况并未反映2024年1月结束的注册直接发行,总收益约为1,400万美元。
  • 研发费用:截至2023年12月31日止年度的研发费用为4,360万美元,而截至2022年12月31日的年度为4,980万美元,减少了620万美元。截至2023年12月31日止年度的研发费用包括460万美元的非现金股票支出,而截至2022年12月31日止年度的非现金股票支出为280万美元。
  • 并购费用:截至2023年12月31日和2022年12月31日止年度的一般和管理费用均为870万美元。截至2023年12月31日止年度的一般和管理费用包括270万美元的非现金股票支出,而截至2022年12月31日止年度的非现金股票支出为250万美元。
    • 净亏损:截至2023年12月31日止年度,归属于普通股股东的净亏损为5,180万美元,合每股亏损3.17美元,而截至2022年12月31日止年度的净亏损为6,260万美元,合每股亏损7.09美元。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发